Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Other Accumulated Expenses (2016 - 2025)

CorMedix's Other Accumulated Expenses history spans 11 years, with the latest figure at $2.3 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 1749.19% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $2.3 million, up 1749.19%, while the annual FY2025 figure was $2.3 million, 1749.19% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $2.3 million at CorMedix, up from $278684.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $2.3 million in Q4 2025 and bottomed at $54763.0 in Q3 2023.
  • The 5-year median for Other Accumulated Expenses is $111260.0 (2023), against an average of $248060.2.
  • The largest YoY upside for Other Accumulated Expenses was 1749.19% in 2025 against a maximum downside of 68.76% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $94736.0 in 2021, then plummeted by 31.96% to $64456.0 in 2022, then decreased by 15.04% to $54763.0 in 2023, then soared by 126.43% to $124000.0 in 2024, then skyrocketed by 1749.19% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Other Accumulated Expenses are $2.3 million (Q4 2025), $278684.0 (Q3 2025), and $136298.0 (Q2 2025).